Clinical Trial Search

Primary: Objective Response Rate (ORR, CR+PR) in Patients With Advanced/Metastatic UC Treated With the Combination of Gemcitabine, Cisplatin, and Sunitinib. — 48.5 Percentage of…

Primary: Objective Response Rate (ORR) — 1; 2 Participants

Primary: Number of Participants With Complete Response at 3 Months — 26 Participants

Primary: Median Overall Survival — 13.9 months

Primary: Phase Ib: Safety of Pembrolizumab in Combination With Gemcitabine-Cisplatin — 0 Participants

Primary: The Primary Efficacy Endpoint Was the Number of Patients Attaining Complete Response (CR) at the End of the Treatment Period (PDE Visit). — 42 Participants

Primary: Number of Participants With Progression-free Survival at 6 Months — 3 Participants

Primary: Percentage of Participants With Progression Free Survival (PFS) at 2 Months — 54 % of participants with PFS

Primary: Complete Response Rate at 3 Months — 39 percentage of participants

Primary: Treatment Schedule A: 12-Week Efficacy, Treatment Schedule B: 13-Week Efficacy — 40.9; 39.1 percentage of patients

Primary: Complete Response (CR) Rate for UGN-102 Treatment — 65.1 percentage of patients

Primary: Real-World Overall Survival — 16.8 months

Primary: Pathologic Complete Response Rate by Transurethral Resection of Bladder Tumor (TURBT) and Imaging Studies After Chemotherapy — 46 percentage of participants

Primary: Bladder Tumor Recurrence Rate — 41.37 percentage of subjects

Primary: Best Tumor Response (Complete [CR] or Partial Response [PR] by Response Evaluation Criteria in Solid Tumors [RECIST]) — 0; 0 participants

Primary: Percentage of Participants With Adverse Events (AEs) — 900 Participants

Primary: Objective Tumour Response According to RECIST Criteria — 14.0 Percentage of participants

Primary: Overall Objective Response — 3; 29; 39 participants

Primary: Progression Free Survival — 1.9 Months

Primary: Response Rate — 11 percentage of participants

Primary: Objective Response Rate (ORR) — 69.6; 33.3 Percentage of participants

Primary: Overall Survival (OS) — 10.3; 9.0 months — p=0.0870

Primary: Evaluate the Time to Disease Progression — 6.5; 13.9 months

Primary: Objective Response Rate (ORR) - Central Assessment — 19.5; 21.6; 19.4; 23.8 percentage of participants — p==0.6991

Primary: Progression Free Survival — 8.2 months

Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0; 0 Participants

Primary: Tumor Response Rate — 4.5 percentage of responders

Primary: Objective Response Rate — 8.3 Percentage of participants

Primary: Pathologic Response Rate (PaR) at Time of Radical Cystectomy. PaR is Defined as Absence of Residual MIBC at Cystectomy in the Surgical Specimen (Pathologic Down-staging…

Primary: Count of Participants With Response Measured by RECIST 1.1 — 16 Participants